Stockreport

Erasca: New Focus After Restructuring, But Need More Differentiation [Seeking Alpha]

Erasca, Inc.  (ERAS) 
PDF Investing Group Leader Follow Summary Erasca has streamlined its pipeline, now focusing on a phase 3 trial for Naporafenib targeting NRAS-mutant melanoma, showing [Read more]